ArticleOncoimmunology2015
The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review.Frontiers in endocrinology · 2023Pooled it
- Article
- Toripalimab-associated diabetes mellitus: a case report from the community of Southern China.Endocrinology, diabetes & metabolism case reports · 2023Article
- Tumor-mediated immunosuppression and cytokine spreading affects the relation between EMT and PD-L1 status.Frontiers in immunology · 2023Article
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Article
- Advanced Melanoma: Resistance Mechanisms to Current Therapies.Hematology/oncology clinics of North America · 2021Review
- The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?Cellular and molecular life sciences : CMLS · 2021Review
- Molecular Mechanisms of Epithelial to Mesenchymal Transition Regulated by ERK5 Signaling.Biomolecules · 2021Review
- The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.Frontiers in oncology · 2021Article
- The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects.Frontiers in cell and developmental biology · 2021Article
- PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.Frontiers in immunology · 2021Article
- Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.Nature reviews. Clinical oncology · 2019Review
- Article
- Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.Cancer discovery · 2017Article
- EMT and inflammation: inseparable actors of cancer progression.Molecular oncology · 2017Review
- The Cellular Origin and Evolution of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- The Z-cad dual fluorescent sensor detects dynamic changes between the epithelial and mesenchymal cellular states.BMC biology · 2016Article
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Cell · 2016Article
- Immune Regulation and Antitumor Effect of TIM-1.Journal of immunology research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition and immunosuppression are crucial for cancer metastasis and treatment resistance. The mechanism by which these distinct processes are co-opted remains incompletely understood. Our recent work has exposed the "dirty affairs" of the 2 at the tumor site, thus calling for a combined therapy to break such a dangerous liaison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.